Indaptus Therapeutics (NASDAQ:INDP) Trading Up 15.3% – Should You Buy?

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) rose 15.3% on Thursday . The stock traded as high as $3.65 and last traded at $3.7010. Approximately 462,507 shares traded hands during trading, a decline of 26% from the average daily volume of 623,553 shares. The stock had previously closed at $3.21.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Indaptus Therapeutics Trading Up 15.9%

The company has a market cap of $495.79 million, a PE ratio of -0.59 and a beta of 1.17. The company has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $2.16.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.